Recruiting studies: Mutant Idh1 Inhibitor Olutasidenib
Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibPhase 1/Phase 2 · 5 location(s) · M.D. Anderson Cancer Center · NCT06445959
Look up another condition
Patient organization or foundation? You can brand
this page for your community — your logo, your resources, same honest
registry data, kept current daily.
Ask about branding →
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.